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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, TaiwanTo assess the diagnostic accuracy of 1,3-b-D-glucan (BDG) assay for diagnosing invasive fungal
infections (IFI), we searched the Medline and Embase databases, and studies reporting the per-
formance of BDG assays for the diagnosis of IFI were identified. Our analysis was mainly
focused on the cutoff level. Meta-analysis was performed using conventional meta-analytical
pooling and bivariate analysis. Our meta-analysis covered 28 individual studies, in which 896
out of 4214 patients were identified as IFI positive. The pooled sensitivity, specificity, diag-
nostic odds ratio, and area under the summary receiver operating characteristic (AUC-SROC)
curve were 0.78 [95% confidence interval (CI), 0.75e0.81], 0.81 (95% CI, 0.80e0.83), 21.88
(95% CI, 12.62e37.93), and 0.8855, respectively. Subgroup analyses indicated that in cohort
studies, the cutoff value of BDG at 80 pg/mL had the best diagnostic accuracy, whereas in
caseecontrol studies the cutoff value of 20 pg/mL had the best diagnostic accuracy; moreover,
the AUC-SROC in cohort studies was lower than that in caseecontrol studies. The cutoff value
of 60 pg/mL has the best diagnostic accuracy with the European Organization for Research and
Treatment of Cancer/Mycoses Study Group criteria as a reference standard. The 60 pg/mL cut-
off value has the best diagnostic accuracy with the Fungitell assay compared to the BDG detec-
tion assay. The cutoff value of 20 pg/mL has the best diagnostic accuracy with the Fungitec G-
test assay, and the cutoff value of 11 pg/mL has the best diagnostic accuracy with the Wako
assay. Serum BDG detection is highly accurate for diagnosing IFIs. As such, 60 pg/mL of BDGDepartment, Maanshan Center for Clinical Laboratory, Maanshan Municipal Hospital Group, 45 Hubei
(S. He).
.06.009
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352 S. He et al.level can be used as the best cutoff value to distinguish patients with IFIs from patients without
IFI (mainly due to Candida and Aspergillus).
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The incidence of invasive fungal infections (IFIs) has
markedly increased in recent decades. IFIs are serious and
can lead to life-threatening complications in some patients.
Despite the development of new antifungal drugs, the
mortality rate of IFIs remains high, especially among
intensive care unit patients.1,2 Invasive aspergillosis (IA)
and invasive candidiasis (IC) represent the majority of IFIs
with attributable mortality of 30e40%.3
1,3-b-D-Glucan (BDG) is a fungal-cell-wall polysaccharide
released into the bloodstream of patients with IC, IA, and
other IFIs, except invasive zygomycosis, cryptococcosis,
and Blastomyces dermatitidis.4,5 Therefore, the detection
of BDG is a very interesting tool for IFI diagnosis. The po-
tential role of BDG has been acknowledged by its inclusion
in the revised European Organization for Research and
Treatment of Cancer/Mycoses Study Group (EORTC/MSG)
criteria definitions.6 At present, there are at least three
BDG detection assays developed: Fungitell (Associates of
Cape Code, Inc., East Falmouth, MA, USA), Wako (Wako
Pure Chemical Industries, Ltd., Tokyo, Japan), and
Fungitec-G test (Seikagaku, Kogyo, Tokyo, Japan). Howev-
er, the results of test performances have varied depending
on different assay types, reference standards, and cutoff
values. There are several systematic reviews7,8 about the
accuracy of serum BDG assay for diagnosing IFI focusing on
various factors, and some of them showed a good diagnostic
accuracy of BDG for IFIs, yet excluded assessment of cutoff
subgroups. In this article, we report a new systematic re-
view assessing the diagnostic accuracy of serum BDG for IFIs
on different cutoff values. We also focus on different assay
types, reference standards, and study design for between-
study variability in diagnostic accuracy.Methods
Search strategy and study selection
An overall search of the literature was performed by two
investigators (H.S. and G.F.) using the following sources
from inception through the end of June 2013: Medline
database through PubMed (http://www.ncbi.nlm.nih.gov/
pubmed) and Embase through Scopus (http://www.
scopus.com/home.url). The searching terms were: inva-
sive fungal disease, IFD, invasive fungal infection, IFI,
candidiasis, Candida, aspergillosis, Aspergillus, 1,3-b-D-
glucan, b-D-Glucan, D-glucan, BG, and BDG. Only papers
published in full text were selected, and the language was
restricted to English.We screened the reference lists and abstracts of related
studies, and the full text of potentially relevant publica-
tions of clinical studies reporting measurement of serum
BDG for the diagnosis of IFI were included if: (1) the test
performed was a commercially available BDG assay with
evaluation of the cutoff value for positivity recommended
by the manufacturer: Fungitell, Fungitec-G, and Wako
turbidimetric assay; (2) they used the EORTC/MSG criteria
in 2002 or the revised EORTC/MSG criteria in 2008 (patients
with proven and probable IFIs were considered true positive
cases),6,9 histopathologic examination, microbiological
culture, or autopsy as diagnostic criteria for classification
of IFIs; and (3) data on true positive, true negative, false
positive, and false negative results of the BDG test were
reported separately or could be calculated from the
manuscript. Corresponding authors were contacted for
retrieval of complementary information as needed. Agree-
ment among the three investigators (H.S., Z.L., and Z.D.)
on the above criteria was required for inclusion in the
analysis.
Data extraction and study quality assessment
The final set of articles was assessed by two reviewers (H.S.
and H.J.). Disagreements were resolved by a third author
(W.F.). From each of the included studies, we extracted
data on publication year; name(s) and institution(s) of the
author(s); information on the original sample source; study
design; characteristics of control individuals; numbers of
true positive, false negative, true negative, and false pos-
itive observations; type and manufacturer of the BDG
assay; reference standards; cutoff values for definition of a
positive BG test result; and blinding of investigators to re-
sults. If the article analyzed different BDG cutoff values,
we chose the recommended cutoff value of author(s) for
our meta-analysis. The number of healthy volunteers and
individuals without risk factors was excluded, because they
may lead to overestimation of diagnostic accuracy.10
The methodological quality of the included studies was
assessed by three authors (H.S., H.J., and Z.L.) with the
QUADAS tool.11 Eight of the 14 QUADAS items were
considered relevant for our meta-analysis reference to
another meta-analysis.12 Each item was scored as “yes”,
“no’’, or “unclear”, and agreement of three authors was
required.
Data synthesis and analysis
In order to obtain the outcomes, we performed a compar-
ison to evaluate the diagnostic accuracy of the serum BDG
assay for IFI with MetaDisc version 1.4 (http://www.hrc.es/
investigacion/metadisc_en.htm) based on the random-
Diagnostic accuracy of BDG for IFI 353effects model. Then, we estimated the sensitivity, speci-
ficity, diagnostic odds ratio (DOR) with 95% confidence in-
terval (95% CI), and area under the summary receiver
operating characteristic curve (AUC-SROC) based on
different cutoff values. If the subgroup only included one
study, we calculated the above data using SPSS Statistics 20
(IBM, China). We also performed more stratified (subgroup)
analyses to estimate the effects of study design, reference
standard, and assay type if the subgroup included data of at
least two diagnostic studies. We evaluated the degree of
interstudy statistical heterogeneity using the test of
inconsistency (I2)13 and the Chi-square test14 with RevMan 5
(http://ims.cochrane.org/revman/about-revman-5). A p
value <0.1 for the Chi-square test indicated the presence
of statistical heterogeneity.
Results
Characteristics and quality assessment of the
included studies
As a result of our bibliographical search in PubMed and
Scopus, 28 individual studies that comparatively assessed
the value of BDG testing for the diagnosis of IFI were
included in our review,1,15e41 including 4214 patients, of
which 896 were identified as positive for IFIs with reference
standards. The process used for the selection of studies
that were eligible for inclusion is shown graphically in
Fig. 1.
The characteristics and data on the diagnostic perfor-
mance of BDG assays for IFIs of the 28 included studies are
shown in Table 1. The 28 studies assessed different cutoff
values at 7 pg/mL, 8.9 pg/mL, 10 pg/mL, 11 pg/mL, 20 pg/
mL, 30 pg/mL, 40 pg/mL, 60 pg/mL, 75 pg/mL, 80 pg/mL,Figure 1. Flowchart of study selection. BDG Z 1,3-b-D-
glucan; IFI Z invasive fungal infection; PCP Z Pneumocystis
jirovecii pneumonia.120 pg/mL, 140 pg/mL, and 1000 pg/mL of BDG for the
diagnosis of IFIs. Among the 28 studies included in the
meta-analysis, 15 had a cohort study
design,1,16,17,19e23,25,27,29,31,34,36,38 and the remaining 13
had a caseecontrol design.15,18,24,26,28,30,32,33,35,37,39e41
Seventeen of the 28 studies used EORTC/MSG criteria as
the reference standard,1,15e20,23,24,27e29,31,33,34,36,38 two
referenced autopsy reports,26,41 two used referenced his-
topathologic examination and microbiological culture,21,35
and seven referenced microbiological cultures
only.22,25,30,32,37,39,40 Among the 28 studies, 18 were per-
formed with the Fungitell assay,1,15e19,21e25,28e30,33e35,38
five with the Wako assay,20,27,32,36,39 and five with the
Fungitec G-test assay.26,31,37,40,41
Table 2 presents our assessment of whether each of the
28 studies in our review satisfied the eight items of the
QUADAS tool that were considered relevant to our review.
All studies were performed with acceptable reference
standard and avoided differential verification bias and
incorporation bias. Overall, 96.43% (27/28) of the studies
clearly described study selection criteria.Diagnostic accuracy of BDG for IFI
Table 3 demonstrates the pooled analysis findings for
sensitivity, specificity, DOR, and AUC-SROC of the BDG
assay for IFIs focusing on various factors. The 28 analyzed
studies provided, in total, BDG diagnostic data for 896
patients with IFIs and 3318 control individuals with other
conditions. The bivariate meta-analysis resulted in an
average sensitivity of BDG for the diagnosis of IFI of 0.78
(95% CI, 0.75e0.81) and an average specificity of 0.81
(95% CI, 0.80e0.83; Fig. 2). Additionally, the DOR was
21.88 (95% CI, 12.62e37.93), and the AUC-SROC was
0.8855. The interstudy heterogeneity test of the 28
studies demonstrated that they were statistically signifi-
cantly heterogeneous (c2 Z 135.73, p < 0.00001,
I2 Z 80%; Table 3).
In assessing the diagnostic accuracy for IFIs, there is only
one study that covered each BDG cutoff value at 7 pg/mL,27
8.9 pg/mL,20 10 pg/mL,40 30 pg/mL,26 75 pg/mL,21 120 pg/
mL,34 140 pg/mL,1 and 1000 pg/mL39; two studies with
cutoff values of 11 pg/mL,32,36 20 pg/mL,37,41 and 40 pg/
mL25,31; four studies with 60 pg/mL19,22,33,35; and 10 studies
with 80 pg/mL.15e18,23,24,28e30,38 The pooled sensitivity,
specificity, DOR, and AUC-SROC of the BDG assay for IFI of
each cutoff value, and the results of test of heterogeneity
are displayed in Table 3. The cutoff value of 80 pg/mL was
used for 1932 patients (45.85% of the total patients), of
which 383 were identified as positive for IFIs, and the
pooled sensitivity, specificity, DOR, and AUC-SROC were
0.73 (95% CI, 0.68e0.77), 0.81 (95% CI, 0.79e0.83), 15.66
(95% CI, 8.45e29.03), and 0.8726, respectively. Because
there was only one study focusing on most of the cutoff
values, we divided the cutoff values into four grades:  20
(7 studies), >20 and 60 (7 studies), >60 and 80 (11
studies), and >80 (3 studies). The meta-analysis results of
each grade are shown in Table 3, and only the three studies
in Grade 4 (cutoff value of >80 pg/mL) were not hetero-
geneous (c2 Z 2.09, p Z 0.35, I2 Z 5%).
Table 1 Characteristics of studies included in this meta-analysis
Study Region Study design Assay Cutoff
(pg/mL)
Reference
standards
True þ False þ False e True e
Metan et al 201215 Turkey Caseecontrol study Fungitell 80 EORTC/MSG 33 19 17 59
De Vlieger et al 20111 Belgium Cohort study Fungitell 140 EORTC/MSG 12 10 2 23
Posteraro et al 201116 Italy Cohort study Fungitell 80 EORTC/MSG 15 5 1 74
Acosta et al 201117 Spain Cohort study Fungitell 80 EORTC/MSG 7 7 2 31
Racil et al 201018 Czech Republic Caseecontrol study Fungitell 80 EORTC/MSG 8 55 1 27
Alexander et al 201019 USA Cohort study Fungitell 60 EORTC/MSG 8 54 3 5
Hirata et al 201020 Japan Cohort study Wako 8.9 EORTC/MSG 8 2 2 196
Leon et al 200921 Spain, Argentina,
and France
Cohort study Fungitell 75 Histopathologic
examination,
Microbiological
culture
14 105 4 117
Lunel et al 200922 The Netherlands Cohort study Fungitell 60 Microbiological
culture
16 12 5 18
Hachem et al 200923 USA Cohort study Fungitell 80 EORTC/MSG 29 2 16 18
Koo et al 200924 USA Caseecontrol study Fungitell 80 EORTC/MSG 50 124 23 635
Presterl et al 200925 Austria Cohort study Fungitell 40 Microbiological
culture
12 14 11 44
Obayashi et al 200826 Japan Caseecontrol study Fungitec
G-test
30 Autopsy 39 9 2 98
Senn et al 200827 Switzerland Cohort study Wako 7 EORTC/MSG 20 28 10 85
Persat et al 200828 France Caseecontrol study Fungitell 80 EORTC/MSG 70 39 26 123
Ellis et al 200829 UAE Cohort study Fungitell 80 EORTC/MSG 36 23 2 19
Alam et al 200730 Kuwait Caseecontrol study Fungitell 80 Microbiological
culture
14 0 13 26
Akamatsu et al 200731 Japan Cohort study Fungitec
G-test
40 EORTC/MSG 12 26 7 130
Fujita et al 200632 Japan Caseecontrol study Wako 11 Microbiological
culture
72 28 4 147
Ostrosky-Zeichner
et al 200533
USA Caseecontrol study Fungitell 60 EORTC/MSG 95 22 22 148
Pazos et al 200534 Spain Cohort study Fungitell 120 EORTC/MSG 7 3 1 26
Pickering et al 200535 USA Caseecontrol study Fungitell 60 Histopathologic
examination,
Microbiological
culture
31 10 1 22
Kawazu et al 200436 Japan Cohort study Wako 11 EORTC/MSG 6 2 5 123
Kondori et al 200437 Sweden Caseecontrol study Fungitec
G-test
20 Microbiological
culture
14 0 0 19
Odabasi et al 200438 USA Cohort study Fungitell 80 EORTC/MSG 18 15 2 248
Mori et al 199739 Japan Caseecontrol study Wako 1000 Microbiological
culture
15 1 4 25
Miyazaki et al 199540 Japan Caseecontrol study Fungitec
G-test
10 Microbiological
culture
17 0 7 36
Obayashi et al 199541 Japan Caseecontrol study Fungitec
G-test
20 Autopsy 37 0 4 153
EORTC/MSG Z European Organization for Research and Treatment of Cancer/Mycoses Study Group.
354 S. He et al.Among the 15 cohort studies1,16,17,19e23,25,27,29,31,34,36,38
(accounting for 41.72% of the total number of patients),
the pooled sensitivity, specificity, DOR, and AUC-SROC were
0.75 (95% CI, 0.70e0.80), 0.79 (95% CI, 0.77e0.81), 14.49
(95% CI, 6.37e32.96), and 0.8518, respectively. The cohort
studies assessed cutoff values at 7 pg/mL,27 8.9 pg/mL,20
11 pg/mL,36 40 pg/mL,25,31 60 pg/mL,19,22 75 pg/mL,21
80 pg/mL,16,17,23,29,38 120 pg/mL,34 and 1401 pg/mL of
BDG for the diagnosis of IFIs (results shown in Table 3).Among the 13 caseecontrol studies, the pooled sensitivity,
specificity, DOR, and AUC-SROC were 0.79 (95% CI,
0.76e0.83), 0.83 (95% CI, 0.81e0.85), 36.63 (95% CI,
16.87e79.55), and 0.9210, respectively. The caseecontrol
studies assessed cutoff values of 10 pg/mL,40 11 pg/mL,32
20 pg/mL,37,41 30 pg/mL,26 60 pg/mL,33,35 80 pg/
mL,15,18,24,28,30 and 1000 pg/mL.39 A total of 17 stud-
ies1,15e20,23,24,27e29,31,33,34,36,38 (comprising 69.48% of the
total number of patients) used EORTC/MSG criteria as the
Table 2 Methodological quality assessment of included studies according to eight QUADAS criteria
Study Representative
spectrum
Partial
verification
avoided
Differential
verification
avoided
Incorporation
avoided
Uninterpretable
results
reported
Withdrawals
reported
Clear
description
of study
selection
criteria
Acceptable
reference
standard
Metan et al 201215 Yes Yes Yes Yes Yes Unclear Yes Yes
De Vlieger et al 20111 Yes Yes Yes Yes Yes No Yes Yes
Posteraro et al 201116 Yes Yes Yes Yes Yes No Yes Yes
Acosta et al 201117 Yes Yes Yes Yes Unclear Yes Yes Yes
Racil et al 201018 Yes No Yes Yes Yes Yes Yes Yes
Alexander et al 201019 Yes Yes Yes Yes Unclear Yes Yes Yes
Hirata et al 201020 Yes No Yes Yes Unclear Yes Yes Yes
Leon et al 200921 Yes No Yes Yes Unclear Yes Yes Yes
Lunel et al 200922 Yes No Yes Yes Yes Yes Yes Yes
Hachem et al 200923 Yes Unclear Yes Yes Unclear Unclear Yes Yes
Koo et al 200924 Yes Unclear Yes Yes Yes Yes Yes Yes
Presterl et al 200925 Yes Yes Yes Yes No No Yes Yes
Obayashi et al 200826 No No Yes Yes Yes Yes Yes Yes
Senn et al 200827 Yes Yes Yes Yes Yes Unclear Yes Yes
Persat et al 200828 No Unclear Yes Yes Yes Yes Yes Yes
Ellis et al 200829 Yes Yes Yes Yes Unclear Unclear Yes Yes
Alam et al 200730 No Yes Yes Yes Yes Unclear Yes Yes
Akamatsu et al 200731 Yes Yes Yes Yes Unclear Unclear Yes Yes
Fujita et al 200632 No No Yes Yes Unclear No Yes Yes
Ostrosky-Zeichner
et al 200533
No Unclear Yes Yes Unclear Yes Yes Yes
Pazos et al 200534 Yes Yes Yes Yes Yes Yes Yes Yes
Pickering et al 200535 No No Yes Yes Yes No Yes Yes
Kawazu et al 200436 Yes Yes Yes Yes Unclear Unclear Yes Yes
Kondori et al 200437 No Yes Yes Yes Yes Yes Yes Yes
Odabasi et al 200438 Yes Yes Yes Yes Unclear Yes Yes Yes
Mori et al 199739 Unclear Yes Yes Yes No No Yes Yes
Miyazaki et al 199540 No Yes Yes Yes Yes Unclear Yes Yes
Obayashi et al 199541 No Unclear Yes Yes Unclear Unclear Unclear Yes
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Table 3 Results of meta-analysis for diagnostic accuracy of 1,3-b-D-glucan for invasive fungal infections
Test No. of study Test for heterogeneity Sensitivity (95% CI) Specificity
(95% CI)
Diagnostic odds ratio
(95% CI)
AUC-SROC No. of patients
(%)c2 p I2 (%)
All data 28 135.73 <0.00001 80 0.78 (0.75e0.81) 0.81 (0.80e0.83) 21.88 (12.62e37.93) 0.8855 4214 (100)
Effect of cutoff value (pg/mL)
7 1 d d d 0.67 (0.47e0.83) 0.75 (0.66e0.83) 6.07 (2.54e14.51) 0.6557 143 (3.39)
8.9 1 d d d 0.80 (0.44e0.97) 0.99 (0.96e1.00) 392.00 (48.80e3148.98) 0.8804 208 (4.94)
10 1 d d d 0.71 (0.49e0.87) 1.00 (0.90e1.00) 170.33 (9.20e3154.70) 0.9186 60 (1.42)
11 2 0.06 0.81 0 0.90 (0.81e0.95) 0.90 (0.86e0.93) 88.63 (34.84e225.46) 0.9575 387 (9.18)
20 2 0.11 0.74 0 0.93 (0.82e0.98) 1.00 (0.98e1.00) 1916.70 (179.85e20,426.96) 0.9943 227 (5.39)
30 1 d d d 0.95 (0.83e0.99) 0.92 (0.85e0.96) 212.33 (43.89e1027.24) 0.8963 148 (3.51)
40 2 1.56 0.21 36 0.57 (0.41e0.72) 0.81 (0.75e0.86) 5.41 (2.20e13.30) 0.5956 256 (6.07)
60 4 32.95 <0.00001 91 0.81 (0.74e0.87) 0.67 (0.62e0.73) 6.17 (0.75e50.76) 0.8973 484 (11.49)
75 1 d d d 0.78 (0.52e0.94) 0.53 (0.46e0.59) 3.90 (1.24e12.22) 0.5423 240 (5.70)
80 10 23.66 0.005 62 0.73 (0.68e0.77) 0.81 (0.79e0.83) 15.66 (8.45e29.03) 0.8726 1932 (45.85)
120 1 d d d 0.88 (0.47e1.00) 0.90 (0.73e0.98) 60.67 (5.44e676.92) 0.8315 37 (0.88)
140 1 d d d 0.86 (0.57e0.98) 0.70 (0.51e0.84) 13.80 (2.60e73.38) 0.7327 47 (1.12)
1000 1 d d d 0.79 (0.54e0.94) 0.96 (0.80e1.00) 93.75 (9.56e919.22) 0.8998 45 (1.07)
20 7 37.06 <0.00001 84 0.84 (0.79e0.89) 0.93 (0.91e0.94) 136.93 (25.50e735.17) 0.9510 1025 (24.32)
>20 and 60 7 51.99 <0.00001 88 0.79 (0.74e0.84) 0.76 (0.73e0.79) 9.62 (2.62e35.31) 0.8466 888 (21.07)
>60 and 80 11 26.75 0.003 63 0.73 (0.69e0.78) 0.78 (0.76e0.80) 13.53 (7.52e24.36) 0.8614 2172 (51.54)
>80 3 2.09 0.35 5 0.83 (0.68e0.93) 0.84 (0.75e0.91) 33.15 (9.89e111.12) 0.9149 129 (3.06)
Effect of study design
Cohort study 15 68.57 <0.00001 80 0.75 (0.70e0.80) 0.79 (0.77e0.81) 14.49 (6.37e32.96) 0.8518 1758 (41.72)
40 2 1.56 0.21 36 0.57 (0.41e0.72) 0.81 (0.75e0.86) 5.41 (2.20e13.30) 0.5956 256 (6.07)
60 2 8.22 0.004 88 0.75 (0.57e0.89) 0.26 (0.17e0.36) 1.14 (0.06e21.05) 0.8412 121 (2.87)
80 5 8.99 0.06 55 0.82 (0.74e0.88) 0.88 (0.85e0.91) 38.33 (12.19e120.49) 0.9284 570 (13.53)
Caseecontrol
study
13 62.36 <0.00001 81 0.79 (0.76e0.83) 0.83 (0.81e0.85) 36.63 (16.87e79.55) 0.9210 2456 (58.28)
20 2 0.11 0.74 0 0.93 (0.82e0.98) 1.00 (0.98e1.00) 1916.70 (179.85e20,426.96) 0.9943 227 (5.39)
60 2 0.10 0.75 0 0.83 (0.75e0.89) 0.83 (0.78e0.88) 29.94 (16.16e55.45) 0.9069 363 (8.61)
80 5 3.82 0.43 0 0.69 (0.63e0.74) 0.79 (0.76e0.81) 8.96 (6.36e12.61) 0.7959 1362 (32.32)
Effect of reference standard
EORTC/MSG 17 71.19 <0.00001 78 0.75 (0.72e0.79) 0.82 (0.80e0.83) 15.42 (8.54e27.83) 0.8575 2928 (69.48)
60 2 29.36 <0.00001 97 0.80 (0.73e0.87) 0.67 (0.60e0.73) 2.84 (0.03e313.45) 0.8804 357 (8.47)
80 9 22.39 0.004 64 0.75 (0.70e0.79) 0.81 (0.79e0.83) 14.90 (7.94e27.95) 0.8716 1879 (44.59)
Autopsy 2 2.16 0.14 54 0.93 (0.85e0.97) 0.97 (0.94e0.98) 535.62 (49.98e5740.55) 0.9818 342 (8.12)
Histopathologic
examination and
Microbiological
culture
2 3.84 0.05 74 0.85 (0.69e0.95) 0.57 (0.51e0.63) 10.73 (1.05e109.38) 0.1517 316 (7.50)
Microbiological
culture
7 33.49 <0.00001 82 0.78 (0.72e0.84) 0.85 (0.81e0.89) 38.15 (8.00e181.80) 0.9149 574 (13.62)
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Diagnostic accuracy of BDG for IFI 357reference standard, and their pooled sensitivity, speci-
ficity, DOR, and AUC-SROC were 0.75 (95% CI, 0.72e0.79),
0.82 (95% CI, 0.80e0.83), 15.42 (95% CI, 8.54e27.83), and
0.8575, respectively. The AUC-SROC of the other reference
standards such as autopsy, histopathologic examination and
microbiological culture, and single microbiological culture
were 0.9818, 0.1517, and 0.9149, respectively. The histo-
pathologic examination and microbiological culture group
had a lower accuracy statistically than EORTC/MSG, au-
topsy, and single microbiological culture. When stratified
analysis was conducted based on the findings of the assay
type, the AUC-SROC of Fungitell, Wako, and Fungitec G-test
were 0.8514, 0.9293, and 0.9663, respectively. The diag-
nostic accuracy was significantly lower in the Fungitell
assay than in the Wako and Fungitec G-test assays.
BDG assay for patients with Candida or Aspergillus
infection
Of the 28 included studies, five studies provided specific
data regarding the sensitivity of BDG assay for
IC,21,22,30,32,37 six studies provided data for IA,1,15,17,34e36
and 13 studies provided the respective data regarding the
sensitivity of BDG testing for both patients with IC and
patients with IA16,19,23,24,26e28,31,33,38e41 (all data shown in
Table 4). The total data in Table 4 indicate that the per-
formance of BDG testing for the detection of IC did not
differ considerably from its performance for the detection
of IA (Pearson c2 Z 0.517, p Z 0.472).
Discussion
Our meta-analysis indicated that serum BDG measure-
ment had a good diagnostic accuracy for the diagnosis of
IFIs. In our main analysis, when comparing patients who
had proven or probable IFIs with patients who did not
have IFIs, the AUC-SROC was 0.8855. A value between
0.80 and 0.90 has traditionally been considered to indi-
cate good diagnostic test accuracy, and a value >0.90
indicates a very high overall diagnostic accuracy of the
test. We also assessed the diagnostic accuracy of
different cutoff values of BDG for IFI. There are four
levels of cutoff values (7 pg/mL, 40 pg/mL, 75 pg/mL,
and 140 pg/mL) applied to 686 patients (16.28% of the
total number of patients), with AUC-SROCs < 0.80.
Fortunately, most cutoff values (accounting for 83.72% of
the total number of patients) have a good diagnostic test
accuracy, particularly at the level of 20 pg/mL, and a
very high diagnostic accuracy with an AUC-SROC of
0.9943. When we divided the cutoff values into four
grades, AUC-SROCs of 20 pg/mL and >80 pg/mL were
0.9510 and 0.9149, respectively, indicating a very high
diagnostic accuracy of BDG for IFIs.
However, the above findings should be interpreted in the
light of the high statistical heterogeneity that we noted
among the studies for all analyses. The potential sources of
heterogeneity among the included studies are differences
among cutoff levels, study design, reference standard, and
BDG detection assays. Therefore, we performed stratified
(subgroup) analyses focusing on these factors, and the re-
sults indicated that there was no heterogeneity in the total
Figure 2. Forest plot of the pooled (A) sensitivity and (B) specificity of 1,3-b-D-glucan levels for the diagnosis of invasive fungal
infections.
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Table 4 Sensitivity of 1,3-b-D-glucan testing for invasive candidiasis compared with invasive aspergillosis as reported in
different studies
Study Cutoff (pg/mL) Invasive candidiasis,
proportion (%)
Invasive aspergillosis,
proportion (%)
Metan et al 201215 80 d 33/50 (66.00)
De Vlieger et al 20111 140 d 12/14 (85.71)
Posteraro et al 201116 80 14/15 (93.33) 1/1 (100.00)
Acosta et al 201117 80 d 7/9 (77.78)
Alexander et al 201019 60 7/8 (87.50) 4/7 (57.14)
Leon et al 200921 75 14/18 (77.78) d
Lunel et al 200922 60 16/21 (76.19) d
Hachem et al 200923 80 13/21 (61.90) 14/21 (66.67)
Koo et al 200924 80 26/41 (63.41) 24/32 (75.00)
Obayashi et al 200826 30 3/3 (100.00) 28/28 (100.00)
Senn et al 200827 7 10/17 (58.82) 9/15 (60.00)
Persat et al 200828 80 22/26 (84.62) 48/70 (68.57)
Alam et al 200730 80 14/27 (51.85) d
Akamatsu et al 200731 40 7/14 (50.00) 5/5 (100.00)
Fujita et al 200632 11 72/76 (94.74) d
Ostrosky-Zeichner et al 200533 60 76/92 (82.61) 3/3 (100.00)
Pazos et al 200534 120 d 7/8 (87.50)
Pickering et al 200535 60 d 31/32 (96.88)
Kawazu et al 200436 11 d 6/11 (54.55)
Kondori et al 200437 20 14/14 (100.00) d
Odabasi et al 200438 80 9/11 (81.82) 4/4 (100.00)
Mori et al 199739 1000 11/12 (91.67) 4/4 (100.00)
Miyazaki et al 199540 10 11/11 (100.00) 3/3 (100.00)
Obayashi et al 199541 20 0/1 (0.00) 5/5 (100.00)
Total d 339/428 (79.21) 248/322 (77.02)
Diagnostic accuracy of BDG for IFI 359effect of cutoff value of 11 pg/mL used in Wako assay
(c2Z 0.06, pZ 0.81, I2Z 0%), 20 pg/mL used in Fungitec
G-test assay (c2 Z 0.11, p Z 0.74, I2 Z 0%), 40 pg/mL
(c2 Z 1.56, p Z 0.21, I2 Z 36%), and three studies in
>80 pg/mL grade (c2 Z 2.09, p Z 0.35, I2 Z 5%), two
studies in cohort study at the cutoff value of 40 pg/mL
(c2 Z 1.56, p Z 0.21, I2 Z 36%), two studies in case-
econtrol study at the cutoff value of 20 pg/mL (c2Z 0.11,
p Z 0.74, I2 Z 0%) and 60 pg/mL (c2 Z 0.10, p Z 0.75,
I2Z 0%), and five studies in caseecontrol study at 80 pg/mL
(c2 Z 3.82, p Z 0.43, I2 Z 0%).
The summary results of our overall analysis of serum
BDG assay for diagnosing IFIs are similar to those in studies
earlier systematically reviewed by Onishi and colleagues,7
who also analyzed the accuracy focusing on various fac-
tors except the cutoff level. Our review mainly focused on
the differences between cutoff values, and it may be
recognized as a supplement to the earlier review; more-
over, we estimated the differences among the study
design, reference standards, and BDG detection assays on
the cutoff level. The analysis of cohort studies indicated
that the cutoff value of BDG at 80 pg/mL had the best
diagnostic accuracy (with an AUC-SROC of 0.9284),
whereas the caseecontrol studies indicated that the
cutoff value of 20 pg/mL had the best diagnostic accuracy
(with an AUC-SROC of 0.9943), and the AUC-SROC in
cohort studies was lower than that in caseecontrol
studies. When using EORTC/MSG criteria as a reference
standard, the cutoff value of 60 pg/mL has the bestdiagnostic accuracy, with an AUC-SROC of 0.8804.
Regarding BDG detection assay types, the cutoff value of
60 pg/mL has the best diagnostic accuracy with the Fun-
gitell assay (AUC-SROC Z 0.8973), the cutoff value of
20 pg/mL has the best diagnostic accuracy with the Fun-
gitec G-test assay (AUC-SROC Z 0.9943), and the cutoff
value of 11 pg/mL has the best diagnostic accuracy with
the Wako assay (AUC-SROC Z 0.9575).
The present study has several limitations. First, the
quality of the included studies was moderate and differed
in many of their characteristics, which is commonly
observed in diagnostic test accuracy reviews. It cannot be
excluded that the accuracy of BDG testing for the diag-
nosis of IFI may differ between different patient groups.
Second, this study included only full-text and English ar-
ticles, which may lead to some high-quality studies being
excluded from the analysis. The results of this study
require more high-quality studies for confirmation in the
future.
In conclusion, our meta-analysis suggests that measuring
serum BDG levels has a good accuracy in distinguishing
patients with IFIs, from patients without IFIs, mainly due to
Candida and Aspergillus; the performance of BDG testing
for the detection of IC did not differ considerably from its
performance for the detection of IA; the cutoff value of
60 pg/mL has the best diagnostic accuracy with EORTC/MSG
criteria as the reference standard; and the cutoff value of
60 pg/mL has the best diagnostic accuracy with the Fun-
gitell assay, which was approved in 2003 by the United
360 S. He et al.States Food and Drug Administration for the presumptive
diagnosis of IFI; moreover, 60 pg/mL of BDG can be used as
the best cutoff value to distinguish patients with IFIs from
patients without IFI.Conflicts of interest
All authors declare that there is no conflict of interest.References
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